



Advanced Control Formulary® Change Summary Report Effective 07-01-2022

This report highlights all changes (additions, deletions, and removals) to the CVS Caremark® Advanced Control Formulary.

ADDITIONS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Aptiom (eslicarbazepine) oral tablet	Central Nervous System/ Anticonvulsants	Aptiom is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.	To provide an additional option for the treatment of partial-onset seizures.
Auryxia (ferric citrate) oral tablet	Endocrine and Metabolic/ Phosphate Binder Agents	Auryxia is indicated for: <ul style="list-style-type: none"> The treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis. The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. 	To provide a treatment option for hyperphosphatemia and iron deficiency anemia in those with chronic kidney disease.
Azstarys (serdexmethylphenidate-dexmethylphenidate) oral capsule	Central Nervous System/ Attention Deficit Hyperactivity Disorder	Azstarys is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older.	To provide an additional stimulant option for the treatment of ADHD.
Braftovi (encorafenib) oral capsule	Antineoplastic Agents/ Kinase Inhibitors	Braftovi is indicated: <ul style="list-style-type: none"> In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. In combination with cetuximab, for the treatment of adult patients with 	To provide a BRAF inhibitor option for the treatment of melanoma and CRC.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®
 Change Summary Report
 Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.	
Cotellic (cobimetinib) oral tablet	Antineoplastic Agents/ Kinase Inhibitors	Cotellic is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.	To provide a MEK inhibitor option for the treatment of melanoma.
Jornay PM (methylphenidate ext-rel) oral extended-release capsule	Central Nervous System/ Attention Deficit Hyperactivity Disorder	Jornay PM is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older.	To provide an additional stimulant option for the treatment of ADHD.
Mektovi (binimetinib) oral tablet	Antineoplastic Agents/ Kinase Inhibitors	Mektovi is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.	To provide a MEK inhibitor option for the treatment of melanoma.
NuvaRing (ethinyl estradiol-etonogestrel) vaginal ring	Endocrine and Metabolic/ Contraceptives/ Vaginal	NuvaRing is indicated for use by women to prevent pregnancy.	To provide an additional vaginal contraceptive option.
Talicia (amoxicillin-rifabutin-omeprazole delayed-rel) oral delayed-release capsule	Gastrointestinal/ Ulcer Therapy Combinations	Talicia is indicated for the treatment of <i>Helicobacter pylori</i> infection in adults.	To provide an additional option for the treatment of <i>Helicobacter pylori</i> infection.
Zegalogue (dasiglucagon)	Endocrine and Metabolic/ Glucose Elevating Agents	Zegalogue is indicated for the treatment of severe hypoglycemia in pediatric and adult	To provide an additional option for the treatment of severe hypoglycemia.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
subcutaneous solution for injection		patients with diabetes aged 6 years and older.	
Zelboraf (vemurafenib) oral tablet	Antineoplastic Agents/ Kinase Inhibitors	Zelboraf is indicated for the treatment of <ul style="list-style-type: none"> Patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Patients with Erdheim-Chester Disease with BRAF V600 mutation. 	To provide a BRAF inhibitor option for the treatment of melanoma and Erdheim-Chester Disease.

REMOVALS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Afinitor Disperz (everolimus) oral soluble tablet	Antineoplastic Agents/ Kinase Inhibitors	Afinitor Disperz is indicated for: <ul style="list-style-type: none"> The treatment of adult and pediatric patients aged 1 year and older with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. 	Availability of a generic option for the treatment of TSC-associated SEGA and partial-onset seizures. The preferred option on the Advanced Control Formulary is everolimus soluble tablet.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary® Change Summary Report Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Cayston (aztreonam inhalation solution) inhalation solution	Respiratory/ Cystic Fibrosis	Cayston is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with <i>Pseudomonas aeruginosa</i> .	Availability of additional inhaled antibiotics for use in CF. Preferred options on the Advanced Control Formulary include tobramycin inhalation solution and Bethkis (tobramycin inhalation solution).
CitraNatal (prenatal vitamins) oral capsule, oral tablet, oral pack	Nutritional/ Supplements/ Vitamins and Minerals/ Prenatal Vitamins	CitraNatal is indicated for use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers.	Availability of generic options. The preferred options on the Advanced Control Formulary are generic prenatal vitamins.
Dexilant (dexlansoprazole delayed-rel) oral delayed-release capsule	Gastrointestinal/ Proton Pump Inhibitors	Dexilant is indicated in patients 12 years of age and older for: <ul style="list-style-type: none"> • Healing of all grades of erosive esophagitis (EE). • Maintenance of healed EE and relief of heartburn. • Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). 	Availability of generic proton pump inhibitors. Preferred options on the Advanced Control Formulary include esomeprazole delayed-rel, lansoprazole delayed-rel, omeprazole delayed-rel, and pantoprazole delayed-rel tablet.
Duobrii (halobetasol propionate-tazarotene) topical lotion	Topical/ Dermatology/ Antipsoriatics	Duobrii is indicated for the topical treatment of plaque psoriasis in adults.	Availability of additional topical options for the treatment of plaque psoriasis. Preferred options on the Advanced Control Formulary include calcipotriene ointment or solution WITH desoximetasone (except desoximetasone ointment 0.05%), fluocinonide (except fluocinonide cream 0.1%), or Bryhali (halobetasol propionate); Enstilar (calcipotriene-betamethasone dipropionate), or Taclonex (calcipotriene-betamethasone dipropionate).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary® Change Summary Report Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
GlucaGen HypoKit (glucagon, human recombinant) subcutaneous/ intramuscular/ intravenous solution for injection	Endocrine and Metabolic/ Glucose Elevating Agents	GlucaGen HypoKit is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.	Availability of additional options for the treatment of severe hypoglycemia. Preferred options on the Advanced Control Formulary include Baqsimi (glucagon nasal powder), Gvoke (glucagon subcutaneous solution), and Zegalogue (dasiglucagon).
Glucagon Emergency Kit (glucagon, human recombinant) subcutaneous/ intramuscular/ intravenous solution for injection	Endocrine and Metabolic/ Glucose Elevating Agents	Glucagon Emergency Kit is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.	Availability of additional options for the treatment of severe hypoglycemia. Preferred options on the Advanced Control Formulary include Baqsimi (glucagon nasal powder), Gvoke (glucagon subcutaneous solution), and Zegalogue (dasiglucagon).
Juxtapid (lomitapide) oral capsule	Cardiovascular/ Antilipemics/ MTP Inhibitors	Juxtapid is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).	Availability of an additional option for HoFH. The preferred option on the Advanced Control Formulary is Praluent (alirocumab).
Korlym (mifepristone) oral tablet	Endocrine and Metabolic/ Miscellaneous	Korlym is indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.	Availability of additional options for hyperglycemia associated with Cushing's syndrome. Consult doctor for preferred options on the Advanced Control Formulary.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary[®] Change Summary Report Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Lamictal (lamotrigine) oral chewable tablet, oral tablet, oral kit	Central Nervous System/ Anticonvulsants	Lamictal is indicated for: <ul style="list-style-type: none"> • Epilepsy as adjunctive therapy in patients aged 2 years and older: <ul style="list-style-type: none"> ○ Partial-onset seizures. ○ Primary generalized tonic-clonic seizures. ○ Generalized seizures of Lennox-Gastaut syndrome. • Epilepsy as monotherapy in patients aged 16 years and older: <ul style="list-style-type: none"> ○ Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. • Bipolar disorder: <ul style="list-style-type: none"> ○ Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. 	Availability of additional anticonvulsant options. Preferred options on the Advanced Control Formulary include carbamazepine, carbamazepine ext-rel, clobazam, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, rufinamide, tiagabine, topiramate, valproic acid, zonisamide, Aptiom (eslicarbazepine), Fycompa (perampanel), Oxtellar XR (oxcarbazepine ext-rel), Trokendi XR (topiramate ext-rel), Vimpat (lacosamide), and Xcopri (cenobamate).
Lamictal ODT (lamotrigine orally disintegrating tablet) orally disintegrating tablet, oral kit	Central Nervous System/ Anticonvulsants	Lamictal is indicated for: <ul style="list-style-type: none"> • Epilepsy as adjunctive therapy in patients aged 2 years and older: <ul style="list-style-type: none"> ○ Partial-onset seizures. ○ Primary generalized tonic-clonic seizures. 	Availability of additional anticonvulsant options. Preferred options on the Advanced Control Formulary include carbamazepine, carbamazepine ext-rel, clobazam, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel,

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary® Change Summary Report Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> ○ Generalized seizures of Lennox-Gastaut syndrome. • Epilepsy as monotherapy in patients aged 16 years and older: <ul style="list-style-type: none"> ○ Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. • Bipolar disorder: <ul style="list-style-type: none"> ○ Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. 	levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, rufinamide, tiagabine, topiramate, valproic acid, zonisamide, Aptiom (eslicarbazepine), Fycompa (perampanel), Oxtellar XR (oxcarbazepine ext-rel), Trokendi XR (topiramate ext-rel), Vimpat (lacosamide), and Xcopri (cenobamate).
Lamictal XR (lamotrigine ext-rel) oral extended-release tablet, oral kit	Central Nervous System/ Anticonvulsants	Lamictal XR is indicated for: <ul style="list-style-type: none"> • Adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. • Conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug. 	Availability of additional anticonvulsant options. Preferred options on the Advanced Control Formulary include carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, tiagabine, topiramate, valproic acid, zonisamide, Aptiom (eslicarbazepine), Fycompa (perampanel), Oxtellar XR (oxcarbazepine ext-rel),

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary® Change Summary Report Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Mekinist (trametinib) oral tablet	Antineoplastic Agents/ Kinase Inhibitors	Mekinist is indicated: <ul style="list-style-type: none"> • As monotherapy in BRAF-inhibitor treatment-naïve patients for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. • In combination with dabrafenib for: <ul style="list-style-type: none"> ○ The treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ○ The adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ○ The treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ○ The treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF 	Trokendi XR (topiramate ext-rel), Vimpat (lacosamide), and Xcopri (cenobamate). Availability of additional MEK inhibitor options for the treatment of melanoma. Preferred options on the Advanced Control Formulary include Cotellic (cobimetinib) and Mektovi (binimetinib).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary® Change Summary Report Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		V600E mutation and with no satisfactory locoregional treatment options.	
Movantik (naloxegol) oral tablet	Gastrointestinal/ Opioid-Induced Constipation	Movantik is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.	Availability of additional options for the treatment of OIC. Preferred options on the Advanced Control Formulary include lubiprostone and Symproic (naldemedine).
Pentasa (mesalamine ext-rel) oral extended-release capsule	Gastrointestinal/ Inflammatory Bowel Disease/ Oral Agents	Pentasa is indicated for the induction of remission and for the treatment of adult patients with mildly to moderately active ulcerative colitis.	Availability of additional options for the treatment of mildly to moderately active ulcerative colitis. Preferred options on the Advanced Control Formulary include balsalazide, mesalamine delayed-rel (except mesalamine delayed-rel tablet 800 mg), mesalamine ext-rel, sulfasalazine, sulfasalazine delayed-rel, and Asacol HD (mesalamine delayed-rel tabs).
QuilliChew ER (methylphenidate ext-rel chewable) oral extended-release chewable tablet	Central Nervous System/ Attention Deficit Hyperactivity Disorder	QuilliChew ER is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).	Availability of additional stimulant options for the treatment of ADHD. Preferred options on the Advanced Control Formulary include amphetamine-dextroamphetamine mixed salts ext-rel (not including certain NDCs), dexamethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel (not including certain NDCs), Azstarys (serdexmethylphenidate-dexamethylphenidate), Jornay PM (methylphenidate ext-rel), Mydayis

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary® Change Summary Report Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
			(amphetamine-dextroamphetamine mixed salts ext-rel), and Vyvanse (lisdexamfetamine).
Quillivant XR (methylphenidate ext-rel susp) oral extended-release suspension	Central Nervous System/ Attention Deficit Hyperactivity Disorder	Quillivant XR is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).	Availability of additional stimulant options for the treatment of ADHD. Preferred options on the Advanced Control Formulary include amphetamine-dextroamphetamine mixed salts ext-rel (not including certain NDCs), dexamethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel (not including certain NDCs), Azstarys (serdexmethylphenidate-dexamethylphenidate), Jornay PM (methylphenidate ext-rel), Mydayis (amphetamine-dextroamphetamine mixed salts ext-rel), and Vyvanse (lisdexamfetamine).
Tafinlar (dabrafenib) oral capsule	Antineoplastic Agents/ Kinase Inhibitors	Tafinlar is indicated: <ul style="list-style-type: none"> • As monotherapy for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. • In combination with trametinib, for: <ul style="list-style-type: none"> ○ The treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ○ The adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement 	Availability of additional BRAF inhibitor options for the treatment of melanoma. Preferred options on the Advanced Control Formulary include Braftovi (encorafenib) and Zelboraf (vemurafenib).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®
 Change Summary Report
 Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		of lymph node(s), following complete resection. <ul style="list-style-type: none"> ○ The treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ○ The treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. 	
Generic Agents:			
dexlansoprazole delayed-rel oral delayed-release capsule	Gastrointestinal/ Proton Pump Inhibitors	Dexlansoprazole delayed-rel is indicated in patients 12 years of age and older for: <ul style="list-style-type: none"> • Healing of all grades of erosive esophagitis (EE). • Maintenance of healed EE and relief of heartburn. • Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). 	Availability of additional generic proton pump inhibitors. Preferred options on the Advanced Control Formulary include esomeprazole delayed-rel, lansoprazole delayed-rel, omeprazole delayed-rel, and pantoprazole delayed-rel tablet.
diclofenac potassium tablet 25 mg oral tablet	Analgesics/ NSAIDs	Diclofenac potassium tablets are indicated: <ul style="list-style-type: none"> • For treatment of primary dysmenorrhea. • For relief of mild to moderate pain. • For relief of the signs and symptoms of osteoarthritis. 	Availability of additional generic NSAIDs for pain management. Preferred options on the Advanced Control Formulary include diclofenac sodium, ibuprofen, meloxicam tablet,

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary® Change Summary Report Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> For relief of the signs and symptoms of rheumatoid arthritis. 	and naproxen (except naproxen CR or naproxen suspension).
EluRyng (ethinyl estradiol-etonogestrel) vaginal ring	Endocrine and Metabolic/ Contraceptives/ Vaginal	EluRyng is indicated for use by women to prevent pregnancy.	Availability of additional vaginal contraceptive options. Preferred options on the Advanced Control Formulary include Annovera (ethinyl estradiol-segesterone acetate) and NuvaRing (ethinyl estradiol-etonogestrel).
ethinyl estradiol-etonogestrel vaginal ring	Endocrine and Metabolic/ Contraceptives/ Vaginal	Ethinyl estradiol-etonogestrel is indicated for use by women to prevent pregnancy.	Availability of additional vaginal contraceptive options. Preferred options on the Advanced Control Formulary include Annovera (ethinyl estradiol-segesterone acetate) and NuvaRing (ethinyl estradiol-etonogestrel).
Lofena (diclofenac potassium) oral tablet	Analgesics/ NSAIDs	Lofena is indicated: <ul style="list-style-type: none"> For treatment of primary dysmenorrhea. For relief of mild to moderate pain. For relief of the signs and symptoms of osteoarthritis. For relief of the signs and symptoms of rheumatoid arthritis. 	Availability of additional NSAIDs for pain management. Preferred options on the Advanced Control Formulary include diclofenac sodium, ibuprofen, meloxicam tablet, and naproxen (except naproxen CR or naproxen suspension).

OTHER:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary® Change Summary Report Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Rinvoq (upadacitinib) oral extended-release tablet	Immunologic Agents/ Autoimmune Agents (Self-Administered)	Rinvoq is indicated for the treatment of: <ul style="list-style-type: none"> • Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers • Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers • Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable 	Now preferred for ulcerative colitis after failure of Humira (adalimumab). Note: Rinvoq remains preferred for atopic dermatitis, psoriatic arthritis, and rheumatoid arthritis.
Xeljanz (tofacitinib) oral tablet, oral solution	Immunologic Agents/ Autoimmune Agents (Self-Administered)	Xeljanz is indicated for the treatment of: <ul style="list-style-type: none"> • Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers • Adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers • Adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers 	Now excluded for ankylosing spondylitis. Note: Xeljanz remains excluded for psoriatic arthritis. Xeljanz remains preferred for rheumatoid arthritis and ulcerative colitis.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®
 Change Summary Report
 Effective 07-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> • Adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers • Active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers 	
Xeljanz XR (tofacitinib ext-rel) oral extended-release tablet	Immunologic Agents/ Autoimmune Agents (Self-Administered)	Xeljanz XR is indicated for the treatment of: <ul style="list-style-type: none"> • Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers • Adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers • Adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers • Adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers 	Now excluded for ankylosing spondylitis. Note: Xeljanz XR remains excluded for psoriatic arthritis. Xeljanz XR remains preferred for rheumatoid arthritis and ulcerative colitis.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.



Advanced Control Formulary®
Change Summary Report
Effective 07-01-2022

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.